High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib

Brain metastases (BMs) and bone metastases seriously affect the prognosis of lung cancer patients. How to optimize the use of existing targeted drugs is an important way to address the clinical needs of the central nervous system in the individualized treatment of non-small cell lung cancer (NSCLC)....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ying, Zhang, Xiaowen, Wang, Fang, Feng, Yan, Tang, Huaping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546288/
https://www.ncbi.nlm.nih.gov/pubmed/34722896
http://dx.doi.org/10.1515/med-2021-0379
_version_ 1784590162520440832
author Zhang, Ying
Zhang, Xiaowen
Wang, Fang
Feng, Yan
Tang, Huaping
author_facet Zhang, Ying
Zhang, Xiaowen
Wang, Fang
Feng, Yan
Tang, Huaping
author_sort Zhang, Ying
collection PubMed
description Brain metastases (BMs) and bone metastases seriously affect the prognosis of lung cancer patients. How to optimize the use of existing targeted drugs is an important way to address the clinical needs of the central nervous system in the individualized treatment of non-small cell lung cancer (NSCLC). In this report, we describe an NSCLC patient with BMs who survived for 58 months, which is the longest survival case among lung cancer patients with BMs. The patient was initially diagnosed with lung cancer more than 5 years ago with simultaneous brain, bone, and lung metastases. After gefitinib resistance, she received osimertinib in sequence with no progress for 58 months in total and maintained very good quality of life.
format Online
Article
Text
id pubmed-8546288
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher De Gruyter
record_format MEDLINE/PubMed
spelling pubmed-85462882021-10-29 High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib Zhang, Ying Zhang, Xiaowen Wang, Fang Feng, Yan Tang, Huaping Open Med (Wars) Case Report Brain metastases (BMs) and bone metastases seriously affect the prognosis of lung cancer patients. How to optimize the use of existing targeted drugs is an important way to address the clinical needs of the central nervous system in the individualized treatment of non-small cell lung cancer (NSCLC). In this report, we describe an NSCLC patient with BMs who survived for 58 months, which is the longest survival case among lung cancer patients with BMs. The patient was initially diagnosed with lung cancer more than 5 years ago with simultaneous brain, bone, and lung metastases. After gefitinib resistance, she received osimertinib in sequence with no progress for 58 months in total and maintained very good quality of life. De Gruyter 2021-10-25 /pmc/articles/PMC8546288/ /pubmed/34722896 http://dx.doi.org/10.1515/med-2021-0379 Text en © 2021 Ying Zhang et al., published by De Gruyter https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License.
spellingShingle Case Report
Zhang, Ying
Zhang, Xiaowen
Wang, Fang
Feng, Yan
Tang, Huaping
High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib
title High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib
title_full High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib
title_fullStr High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib
title_full_unstemmed High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib
title_short High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib
title_sort high quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546288/
https://www.ncbi.nlm.nih.gov/pubmed/34722896
http://dx.doi.org/10.1515/med-2021-0379
work_keys_str_mv AT zhangying highqualityof58monthlifeinlungcancerpatientwithbrainmetastasessequentiallytreatedwithgefitinibandosimertinib
AT zhangxiaowen highqualityof58monthlifeinlungcancerpatientwithbrainmetastasessequentiallytreatedwithgefitinibandosimertinib
AT wangfang highqualityof58monthlifeinlungcancerpatientwithbrainmetastasessequentiallytreatedwithgefitinibandosimertinib
AT fengyan highqualityof58monthlifeinlungcancerpatientwithbrainmetastasessequentiallytreatedwithgefitinibandosimertinib
AT tanghuaping highqualityof58monthlifeinlungcancerpatientwithbrainmetastasessequentiallytreatedwithgefitinibandosimertinib

Ejemplares similares